Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Metformin + Sitagliptin & Type 2 Diabetes (T2D)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Regulatory status

In the context of Metformin + Sitagliptin & Type 2 Diabetes (T2D), metformin + sitagliptin is an approved, guideline‑recommended dual combination for T2D in both the US (FDA) and EU (EMA). However, on 22 July 2025, the marketing authorization of Sitagliptin/Metformin Hydrochloride Accord (sitagliptin / metformin hydrochloride) ceased to be valid in the European Union (EU).
Reynolds 2009 Diabetes Metab Syndr Obes 2: 127-34
216778Orig1s000MedR

References (Sources)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
Reynolds 2009 Diabetes Metab Syndr Obes 2: 127-34
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!